meta
|
evidence
oncology
Living systematic review and meta-analysis
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
2
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
5
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab plus ipilimumab
title
placebo
title
CheckMate 451 (NI ; all population), 2019 NCT02538666 Extensive stage SCLC (Es-SCLC) - maintenance (M) 279/275
Pathology:
Extensive stage SCLC (Es-SCLC) - maintenance (M);
Extensive stage SCLC (Es-SCLC) - maintenance (M)
CheckMate 451 (NI ; all population), 2019
nivolumab plus ipilimumab
1
T1
placebo
0
T0